SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed.
The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Heart Attack | Metformin | SGLT2 Inhibitors | Stroke | Study